Frank Porreca

List of Publications by Year
in descending order

105 papers	4,868 citations	109321 35 h-index	110387 64 g-index
106 all docs	106 docs citations	106 times ranked	5194 citing authors

#	Article	IF	Citations
1	Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. Brain, 2023, 146, 1186-1199.	7.6	8
2	A prolactin-dependent sexually dimorphic mechanism of migraine chronification. Cephalalgia, 2022, 42, 197-208.	3.9	14
3	Relief of neuropathic pain by cell-specific manipulation of nucleus accumbens dopamine D1- and D2-receptor-expressing neurons. Molecular Brain, 2022, 15, 10.	2.6	14
4	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache. Cephalalgia, 2022, , 033310242210998.	3.9	3
5	Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents. Cellular and Molecular Neurobiology, 2021, 41, 949-960.	3.3	6
6	Green Light Exposure Improves Pain and Quality of Life in Fibromyalgia Patients: A Preliminary One-Way Crossover Clinical Trial. Pain Medicine, 2021, 22, 118-130.	1.9	26
7	A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. Cephalalgia, 2021, 41, 305-317.	3.9	21
8	Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial. Cephalalgia, 2021, 41, 135-147.	3.9	29
9	CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. Cephalalgia, 2021, 41, 749-759.	3.9	17
10	The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 278-284.	3.4	97
11	Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors. Neuropharmacology, 2021, 185, 108456.	4.1	25
12	Cognition in the Chronic Pain Experience: Preclinical Insights. Trends in Cognitive Sciences, 2021, 25, 365-376.	7.8	38
13	Multifunctional Enkephalin Analogs with a New Biological Profile: MOR/DOR Agonism and KOR Antagonism. Biomedicines, 2021, 9, 625.	3.2	5
14	Chronic Pain Produces Reversible Memory Deficits That Depend on Task Difficulty in Rats. Journal of Pain, 2021, 22, 1467-1476.	1.4	5
15	A new hypothesis linking oxytocin to menstrual migraine. Headache, 2021, 61, 1051-1059.	3.9	11
16	Introducing descending control of nociception: a measure of diffuse noxious inhibitory controls in conscious animals. Pain, 2021, 162, 1957-1959.	4.2	17
17	Sexual dimorphism in functional pain syndromes. Science Translational Medicine, 2021, 13, eabj7180.	12.4	12
18	Decreased dopaminergic inhibition of pyramidal neurons in anterior cingulate cortex maintains chronic neuropathic pain. Cell Reports, 2021, 37, 109933.	6.4	27

#	Article	IF	Citations
19	C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters. Bioorganic and Medicinal Chemistry, 2021, 51, 116509.	3.0	1
20	Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia, 2020, 40, 68-78.	3.9	15
21	Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. Pain, 2020, 161, 609-618.	4.2	34
22	An Emerging Role for Prolactin in Female-Selective Pain. Trends in Neurosciences, 2020, 43, 635-648.	8.6	25
23	Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Cephalalgia, 2020, 40, 1535-1550.	3.9	17
24	Amygdala, neuropeptides, and chronic pain-related affective behaviors. Neuropharmacology, 2020, 170, 108052.	4.1	109
25	Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia, 2020, 40, 892-902.	3.9	47
26	Impact of chronic migraine attacks and their severity on the endogenous Î¼-opioid neurotransmission in the limbic system. NeuroImage: Clinical, 2019, 23, 101905.	2.7	26
27	Post-traumatic headache: epidemiology and pathophysiological insights. Nature Reviews Neurology, 2019, 15, 607-617.	10.1	131
28	CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia, 2019, 39, 1762-1775.	3.9	66
29	Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). Journal of Medicinal Chemistry, 2019, 62, 1761-1780.	6.4	35
30	Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurology, The, 2019, 18, 891-902.	10.2	151
31	Opioid analgesics pass the acid test. Lancet, The, 2019, 393, 1579-1581.	13.7	0
32	Inhibition of experimental visceral pain in rodents by cebranopadol. Behavioural Pharmacology, 2019, 30, 320-326.	1.7	6
33	Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light. Journal of Pain, 2019, 20, 1293-1306.	1.4	15
34	Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. Pain, 2019, 160, 824-832.	4.2	75
35	Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously. Neuron, 2019, 101, 353-355.	8.1	42
36	Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. Pain, 2019, 160, 1614-1621.	4.2	45

#	Article	IF	Citations
37	Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Cephalalgia, 2019, 39, 617-625.	3.9	26
38	Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. Molecular Pain, 2018, 14, 174480691875640.	2.1	57
39	Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system. Molecular Pain, 2018, 14, 174480691875493.	2.1	12
40	The opioid crisis and â€¦ reconsidering the use of drugs that affect body temperature. Temperature, 2018, 5, 1-3.	3.0	2
41	Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. Journal of Controlled Release, 2018, 270, 135-144.	9.9	51
42	Kappa Opioid Receptor Distribution and Function in Primary Afferents. Neuron, 2018, 99, 1274-1288.e6.	8.1	100
43	The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. Neuropharmacology, 2018, 141, 260-271.	4.1	13
44	Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain. Pain, 2018, 159, 2512-2521.	4.2	46
45	Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors. Bioorganic and Medicinal Chemistry, 2018, 26, 3664-3667.	3.0	6
46	Selective deficiencies in descending inhibitory modulation in neuropathic rats: implications for enhancing noradrenergic tone. Pain, 2018, 159, 1887-1899.	4.2	23
47	Engagement of kappa opioid system in the right amygdala diminishes diffuse noxious inhibitory controls (DNIC). Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-2-19.	0.0	0
48	Activation of dura-sensitive trigeminal neurons and increased c-Fos protein induced by morphine withdrawal in the rostral ventromedial medulla. Cephalalgia, 2017, 37, 407-417.	3.9	10
49	Mechanisms of craniofacial pain. Cephalalgia, 2017, 37, 613-626.	3.9	101
50	Long-lasting antinociceptive effects of green light in acute and chronic pain in rats. Pain, 2017, 158, 347-360.	4.2	81
51	Reward, motivation, and emotion of pain and its relief. Pain, 2017, 158, S43-S49.	4.2	119
52	Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics. ACS Chemical Neuroscience, 2017, 8, 1147-1158.	3.5	37
53	Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. Cephalalgia, 2017, 37, 780-794.	3.9	70
54	Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain, 2017, 158, 2386-2395.	4.2	74

#	Article	IF	Citations
55	Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. Cephalalgia, 2017, 37, 1350-1372.	3.9	31
56	Various modifications of the amphipathic dynorphin <scp>A</scp> pharmacophore for rat brain bradykinin receptors. Chemical Biology and Drug Design, 2016, 88, 615-619.	3.2	2
57	Positive emotions and brain reward circuits in chronic pain. Journal of Comparative Neurology, 2016, 524, 1646-1652.	1.6	67
58	Cyclic non-opioid dynorphin A analogues for the bradykinin receptors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5513-5516.	2.2	5
59	Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain. ACS Chemical Neuroscience, 2016, 7, 1746-1752.	3.5	7
60	Structureâ€“Activity Relationships of [des-Arg⁷]Dynorphin A Analogues at the Î¹ Opioid Receptor. Journal of Medicinal Chemistry, 2016, 59, 10291-10298.	6.4	11
61	Efficacy of (S)-lacosamide in preclinical models of cephalic pain. Pain Reports, 2016, 1, e565.	2.7	24
62	(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain, 2016, 157, 1448-1463.	4.2	54
63	Central Sensitization and Neuropathic Features of Ongoing Pain inÂa Rat Model of Advanced Osteoarthritis. Journal of Pain, 2016, 17, 374-382.	1.4	75
64	Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain. Pain, 2016, 157, 2731-2738.	4.2	38
65	Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain, 2015, 138, 28-35.	7.6	120
66	Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist â€“ Neurokinin-1 antagonist peptidomimetics. European Journal of Medicinal Chemistry, 2015, 92, 64-77.	5.5	27
67	Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3716-3720.	2.2	14
68	Endogenous Opioid Activity in the Anterior Cingulate Cortex Is Required for Relief of Pain. Journal of Neuroscience, 2015, 35, 7264-7271.	3.6	154
69	Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4683-4688.	2.2	10
70	Brain Circuits Encoding Reward from Pain Relief. Trends in Neurosciences, 2015, 38, 741-750.	8.6	174
71	Discovery of Novel Multifunctional Ligands with Î¼/Î´ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. Journal of Medicinal Chemistry, 2015, 58, 8573-8583.	6.4	16
72	Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4148-4152.	2.2	4

#	Article	IF	Citations
73	Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands. Bioorganic and Medicinal Chemistry, 2015, 23, 6185-6194.	3.0	2
74	Modification of amphipathic non-opioid dynorphin A analogues for rat brain bradykinin receptors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 30-33.	2.2	11
75	Blockade of non-opioid excitatory effects of spinal Dynorphin A at bradykinin receptors. Receptors & Clinical Investigation, 2015, 2, .	0.9	2
76	Lost but making progressâ€"Where will new analgesic drugs come from?. Science Translational Medicine, 2014, 6, 249sr3.	12.4	102
77	Novel Cyclic Biphalin Analogue with Improved Antinociceptive Properties. ACS Medicinal Chemistry Letters, 2014, 5, 1032-1036.	2.8	30
78	Structureâ€"activity relationships of non-opioid [des-Arg7]-dynorphin A analogues for bradykinin receptors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4976-4979.	2.2	11
79	Reward and motivation in pain and pain relief. Nature Neuroscience, 2014, 17, 1304-1312.	14.8	370
80	The ACTTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. Journal of Pain, 2014, 15, 241-249.	1.4	159
81	The development of bifunctional ligands as novel therapeutics for chronic pain (1061.5). FASEB Journal, 2014, 28, 1061.5.	0.5	0
82	Disease modification of breast cancerâ€"induced bone remodeling by cannabinoid 2 receptor agonists. Journal of Bone and Mineral Research, 2013, 28, 92-107.	2.8	64
83	Chiral Effect of a Phe Residue in Position 3 of the Dmt¹-<scp>l</scp>(or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 3 Letters, 2013, 4, 656-659.	2.8	3
84	New potent biphalin analogues containing p-fluoro-l-phenylalanine at the 4,4â€² positions and non-hydrazine linkers. Amino Acids, 2011, 40, 1503-1511.	2.7	30
85	Triptanâ€induced latent sensitization: A possible basis for medication overuse headache. Annals of Neurology, 2010, 67, 325-337.	5.3	181
86	Nausea and Vomiting Side Effects with Opioid Analgesics during Treatment of Chronic Pain: Mechanisms, Implications, and Management Options. Pain Medicine, 2009, 10, 654-662.	1.9	175
87	Synthesis and biological activity of the first cyclic biphalin analogues. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 367-372.	2.2	39
88	Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2471-2475.	2.2	25
89	Retrovirus-Mediated Expression of an Artificial Î²-Endorphin Precursor in Primary Fibroblasts. Journal of Neurochemistry, 2002, 64, 475-481.	3.9	23
90	?-Azido acids for direct use in solid-phase peptide synthesis. Journal of Peptide Science, 2000, 6, 594-602.	1.4	28

#	Article	IF	Citations
91	Spinal and Supraspinal Mechanisms of Neuropathic Pain. Annals of the New York Academy of Sciences, 2000, 909, 12-24.	3.8	220
92	Exploring the Structureâ^'Activity Relationships of [1-(4-tert-Butyl-3â€˜-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), A High-Affinity and Selective Î´-Opioid Receptor Nonpeptide Agonist Ligandâ€. Journal of Medicinal Chemistry, 1999, 42, 5359-5368.	6.4	29
93	Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat ? opioid receptor. Synapse, 1998, 28, 117-124.	1.2	12
94	Orphanin-FQ/nociceptin: Lack of antinociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. European Journal of Pain, 1998, 2, 267-278.	2.8	25
95	De Novo Design, Synthesis, and Biological Activities of High-Affinity and Selective Non-Peptide Agonists of the Î´-Opioid Receptor. Journal of Medicinal Chemistry, 1998, 41, 4767-4776.	6.4	67
96	Cyclic Enkephalin Analogues with Exceptional Potency and Selectivity for Î´-Opioid Receptors1. Journal of Medicinal Chemistry, 1997, 40, 3957-3962.	6.4	42
97	Peptide Targeting and Delivery across the Bloodâ^'Brain Barrier Utilizing Synthetic Triglyceride Esters:Â Design, Synthesis, and Bioactivity. Bioconjugate Chemistry, 1997, 8, 434-441.	3.6	25
98	Synthesis and biological properties of Î²â€MePhe³ analogues of deltorphin I and dermenkephalin: influence of biased X¹ of Phe³ residues on peptide recognition for Îâ€opioid receptors. Chemical Biology and Drug Design, 1997, 50, 48-54.	1.1	15
99	Effects of Modifications of Residues in Position 3 of Dynorphin A(1â^'11)-NH2on Îº Receptor Selectivity and Potency. Journal of Medicinal Chemistry, 1996, 39, 2456-2460.	6.4	31
100	Design, Synthesis, and Biological Activities of Cyclic Lactam Peptide Analogues of Dynorphin A(1â^'11)-NH21. Journal of Medicinal Chemistry, 1996, 39, 1136-1141.	6.4	31
101	Conformational restriction of Tyr and Phe side chains in opioid peptides: Information about preferred and bioactive side-chain topology. , 1996, 38, 1-12.		73
102	Delta opioid receptor selective ligands; DPLPEâ€deltorphin chimeric peptide analogues^{â€}. International Journal of Peptide and Protein Research, 1994, 44, 80-84.	0.1	8
103	Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10. International Journal of Peptide and Protein Research, 1993, 42, 411-419.	0.1	32
104	Development of delta opioid peptides as nonaddicting analgesics. Pharmaceutical Research, 1991, 08, 1-8.	3.5	105
105	Interaction of ?-funaltrexamine with [3H]cycloFOXY binding in rat brain: Further evidence that ?-FNA alkylates the opioid receptor complex. Synapse, 1991, 8, 86-99.	1.2	22